Evidence map›Paper›PMID 26637322›Full record

ArticleActa neuropathologica communications2015

Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody.

Kazuhiro Kurosawa, Tatsuro Misu, Yoshiki Takai, Douglas Kazutoshi Sato, Toshiyuki Takahashi, Yoichiro Abe, Hiroko Iwanari, Ryo Ogawa, Ichiro Nakashima, Kazuo Fujihara and 3 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Acta neuropathologica communications, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.

  1. A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica.Annals of clinical and translational neurology · 2021
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Kazuhiro KurosawaDepartment of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Tatsuro MisuDepartment of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan. misu@med.tohoku.ac.jp.
Yoshiki TakaiDepartment of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Douglas Kazutoshi SatoDepartment of Multiple Sclerosis Therapeutics, Tohoku University Graduate School of Medicine, Sendai, Japan.
Toshiyuki TakahashiDepartment of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Yoichiro AbeKeio Advanced Research Center for Water Biology and Medicine, Keio University, Tokyo, Japan.
Hiroko IwanariDepartment of Quantitative Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
Ryo OgawaDepartment of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Ichiro NakashimaDepartment of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Kazuo FujiharaDepartment of Multiple Sclerosis Therapeutics, Tohoku University Graduate School of Medicine, Sendai, Japan.
Takao HamakuboDepartment of Quantitative Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
Masato YasuiKeio Advanced Research Center for Water Biology and Medicine, Keio University, Tokyo, Japan.
Masashi AokiDepartment of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Tohoku University · JPKeio University · JPThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNeuromyelitis optica (NMO), an autoimmune astrocytopathic disease associated with anti-aquaporin-4 (AQP4) antibody, is characterized by extensive necrotic lesions preferentially involving the optic nerves and spinal cord. However, previous in-vivo experimental models injecting human anti-AQP4 antibodies only resulted in mild spinal cord lesions compared to NMO autopsied cases. Here, we investigated whether the formation of severe NMO-like lesions occurs in Lewis rats in the context of experimental autoimmune encephalomyelitis (EAE), intraperitoneally injecting incremental doses of purified human immunoglobulin-G from a NMO patient (hIgGNMO) or a high affinity anti-AQP4 monoclonal antibody (E5415A), recognizing extracellular domain of AQP4 made by baculovirus display method.

resultsNMO-like lesions were observed in the spinal cord, brainstem, and optic chiasm of EAE-rats with injection of pathogenic IgG (hIgGNMO and E5415A), but not in control EAE. Only in higher dose E5415A rats, there were acute and significantly severer clinical exacerbations (tetraparesis or moribund) compared with controls, within half day after the injection of pathogenic IgG. Loss of AQP4 was observed both in EAE rats receiving hIgGNMO and E5415A in a dose dependent manner, but the ratio of AQP4 loss in spinal sections became significantly larger in those receiving high dose E5415A up to about 50 % than those receiving low-dose E5415A or hIgGNMO less than 3 %. These lesions were also characterized by extensive loss of glial fibrillary acidic protein but relatively preserved myelin sheaths with perivascular deposition of IgG and C5b-9, which is compatible with post mortem NMO pathology. In high dose E5415A rats, massive neutrophil infiltration was observed especially at the lesion edge, and such lesions were highly vacuolated with partial demyelination and axonal damage. In contrast, such changes were absent in EAE rats receiving low-dose E5415A and hIgGNMO.

conclusionsIn the present study, we established a severe experimental NMO rat model with highly clinical exacerbation and extensive tissue destructive lesions typically observed in NMO patients, which has not adequately been realized in in-vivo rodent models. Our data suggest that the pathogenic antibodies could induce immune mediated astrocytopathy with mobilized neutrophils, resulted in early lesion expansion of NMO lesion with vacuolation and other tissue damages. (350/350).

Indexed as

AgedAnimalsAntibody AffinityAquaporin 4AstrocytesCalcium-Binding ProteinsComplement C9Disease Models, AnimalDose-Response Relationship, DrugFemaleHumansImmunoglobulin GMicrofilament ProteinsNerve Tissue ProteinsNeuromyelitis OpticaNeutrophil InfiltrationAif1 protein, mouseAquaporin 4Calcium-Binding ProteinsComplement C9complement C9 polymerImmunoglobulin GMicrofilament ProteinsNerve Tissue Proteins

Identifiers

PMID26637322
PMCPMC4670539
OpenAlexW2181770355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.